Magnesia Cinfa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magnesia Cinfa

Property Description
Active Ingredient Magnesium Hydroxide (Mg(OH)2)
Form Oral Suspension (Liquid)
Pharmacological Class Non-systemic Antacid / Osmotic Laxative
Primary Action Acid Neutralization and Water Retention
Origin Inorganic compound

What is the Pharmacological Identity of Magnesia Cinfa?

Magnesia Cinfa is a specific medicinal preparation from the manufacturer Cinfa, characterized by the single active ingredient Magnesium Hydroxide, an inorganic compound designed for localized action within the digestive system. Pharmacologically, this over-the-counter (OTC) medicine holds the distinct dual identity of being both a non-systemic antacid and an osmotic laxative. Magnesium Hydroxide is employed in gastroenterology for both its acid-reducing and osmotic properties.

This formulation is clinically recognized for addressing symptoms like occasional heartburn or discomfort linked to stomach acid, and for facilitating bowel movements. The dual mechanism is designed to address these two common, often co-occurring, gastrointestinal concerns.


Magnesia Cinfa Dosage Form and Primary Action

The product is supplied as an Oral Suspension, a liquid dosage form intended for oral ingestion, where the solid Magnesium Hydroxide compound is finely and stably dispersed within an aqueous vehicle. This suspension format is particularly beneficial for patient groups, such as adolescents and adults, who require prompt symptom relief or prefer a liquid over tablets. Oral suspensions based on Magnesium Hydroxide are indicated for gastrointestinal conditions relating to acidity and constipation.

Magnesia Cinfa generally helps by utilizing its dual action profile to address two fundamental symptoms: it provides prompt relief from the discomfort associated with gastric acidity through neutralization, and it facilitates gentle movement for occasional constipation through osmotic water retention.

Regulatory References

  1. MedlinePlus Reference

What side effects are possible with Magnesia Cinfa?

Possible side effects and safety information

The official regulatory documentation for medicines containing Magnesium Hydroxide classifies potential adverse effects primarily related to the digestive system and electrolyte balance. The risk profile is strictly defined by government regulatory texts, which group effects by frequency and impact.

Documented Adverse Reactions and Frequency

Adverse reactions are categorized by frequency based on available data from official sources:

  • Common Reactions: The most frequently documented adverse effect is diarrhea, which is directly linked to the medication's osmotic action as a laxative.
  • Rare Reactions: The most significant systemic safety concern is hypermagnesemia (excessive blood magnesium). This is classified as a rare but serious adverse reaction, primarily observed in susceptible individuals.
  • Frequency Not Known: Other effects documented in the Gastrointestinal Disorders and Immune System Disorders (e.g., hypersensitivity reactions) are listed but lack sufficient data for a definitive frequency estimate.

Safety Considerations and Restrictions

The regulatory profile highlights specific constraints and at-risk populations:

  • Population Restriction (Renal): The use of Magnesium Hydroxide is contraindicated in patients with severe renal impairment due to the significantly increased risk of systemic magnesium accumulation and subsequent hypermagnesemia.
  • Duration-Related Safety: Official safety notes indicate that the risk of systemic effects, including electrolyte disturbances, is elevated with prolonged use or long-term exposure, reinforcing the drug's role as a short-term remedy.
  • Safety Constraints: The medication is also contraindicated in pathological conditions such as confirmed or suspected intestinal obstruction or appendicitis.

This structured safety information ensures that the profile clearly communicates the high likelihood of common gastrointestinal effects and defines the rare but serious systemic risks based on official government labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the overdose profile for Magnesia Cinfa as primarily resulting in symptoms associated with hypermagnesemia (excess magnesium in the blood). Overdose may occur from accidental ingestion or, in patients with pre-existing conditions, from prolonged administration.

Documented Overdose Symptoms

The following clinical manifestations have been documented in cases of overdose:

  • Systemic Symptoms: Flushing, feeling thirsty, generalized fatigue, nausea, and vomiting.
  • Cardiovascular Effects: Hypotension (low blood pressure).
  • Neurological/Musculoskeletal Effects: Confusion, dizziness, blurred vision, disorientation, and muscle weakness.

Population-Specific Overdose Risk

Overdose risk is heightened in certain groups. Regulatory information specifically notes that the use of this drug in young children can cause hypermagnesemia, particularly if they also have renal insufficiency or dehydration. Additionally, hypermagnesemia has been observed following prolonged administration in adults with renal insufficiency.

Emergency Action

Immediate medical help must be sought in the event of suspected overdose or accidental ingestion, even if the person appears well. Official guidance states to consult a doctor or pharmacist immediately or to call the local Toxicology Information Service for urgent assistance.

Therapeutic Uses of Magnesia Cinfa

Quick Facts

  • Relief of Occasional Constipation: Helps address infrequent bowel movements and may soften stools.
  • Antacid Action: May provide temporary relief from symptoms associated with stomach hyperacidity.

Magnesia Cinfa is a formulation that helps manage two distinct therapeutic domains. It is primarily used to provide relief from occasional constipation. The medication works by aiding in the retention of water within the intestines, which promotes softer stools and supports bowel movement. This action may help manage irregularity on a short-term basis.

Additionally, the formulation has an antacid property. In this context, it may be used to provide temporary relief from symptoms associated with stomach hyperacidity, such as heartburn or acid indigestion. The medication is an appropriate option for patients seeking supportive care for these common digestive and bowel discomforts.

As with any medication, the potential risks and benefits should be considered, and it should not be used for chronic conditions without medical guidance.

Regulatory References

  1. NIH MedlinePlus guidance on Magnesium Hydroxide

Eligibility and Restrictions for Use

Who Can and Cannot Use Magnesia Cinfa?

This section defines population eligibility based strictly on official governmental regulatory documentation for Magnesia Cinfa (Magnesium Hydroxide).


Populations with Absolute Contraindications

Use of Magnesia Cinfa is contraindicated and must be avoided in the following groups, as per regulatory labeling:

  • Patients with severe renal insufficiency (severe kidney failure).
  • Patients with hydroelectrolytic imbalance (electrolyte imbalance).
  • Patients with specific gastrointestinal conditions, including abdominal obstruction, appendicitis, or gastrointestinal/rectal bleeding.
  • Individuals with known hypersensitivity to magnesium hydroxide.

Age and Conditional Use Rules

Population Group Eligibility Status Restriction Details
Children under 12 Contraindicated Explicitly prohibited by labeling.
Adults & Adolescents (≥12) Approved Population Approved for use under standard conditions.
Pregnant/Lactating Patients Conditional Use Requires consultation with a doctor before use.
Elderly or Debilitated Conditional Use Requires control due to increased systemic risk.

Organ and Comorbidity Restrictions

Patients with non-severe renal impairment, hepatic insufficiency, or cardiac disease require conditional use and professional oversight. The medicine is also contraindicated for those with specific hereditary absorption disorders, such as hereditary fructose intolerance.

What should I know about interactions with other medicines?

Magnesia Cinfa Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Magnesia Cinfa (Magnesium Hydroxide) around two core constraints: the potential to reduce the absorption of other co-administered drugs and the risk of magnesium accumulation in certain populations.

Interaction Scope: Official Regulatory Constraints

Constraint Area Statement from Regulatory Authorities
Timing-Based Separation Rule Administration of Magnesia Cinfa must be separated from all other medicines by an interval of at least 2 to 3 hours to minimize interference with absorption.
Exposure-Reducing Interactions Official labeling lists multiple agents whose absorption is reduced, potentially lowering their effectiveness. This includes antibiotics (e.g., Fluoroquinolones, Tetracyclines), Bisphosphonates (e.g., Alendronic acid), Iron Salts, and Digoxin.
Pharmacodynamic Interactions The antacid effect may increase the urinary excretion of certain substances, such as Salicylates, which can reduce their concentration in the body.

Interaction Classifications and Restrictions

Classification Type Regulatory Statement
Contraindicated Combination Co-administration with other magnesium-containing products (antacids or laxatives) is formally contraindicated in patients with severe renal impairment.
Population-Specific Note Patients with severe renal impairment are at an increased risk of Hypermagnesemia due to reduced clearance of magnesium, which is considered a condition-dependent interaction severity.

These constraints define the regulatory safety structure for Magnesia Cinfa, mandating procedural separation for most concurrent medications and prohibiting specific combinations in patients with compromised kidney function.

Mechanism of Action

The mechanism of action for Magnesia Cinfa is defined by the dual, non-systemic properties of its single ingredient, Magnesium Hydroxide ( Mg( OH)2), which influences two distinct physiological pathways localized in the gut.


Modulation of Intragastric pH and Pepsin Activity

The compound acts as a direct chemical buffer. Its hydroxide component ( OH^-) immediately engages in an acid-base reaction with stomach H^+ ions, causing a rapid, transient increase in gastric pH toward 4 to 5. This pH elevation is key to the subsequent inactivation of the proteolytic enzyme pepsin, which can only function in highly acidic environments, thereby reducing the concentration of free H^+ ions.


Colonic Fluid Dynamics and Peristaltic Stimulation

The unabsorbed magnesium ions ( Mg^2+) establish an osmotic gradient in the colon, a physicochemical process that draws water from the intestinal lining into the lumen. This increase in intraluminal fluid increases the water content and bulk of the colonic mass and physically distends the colon. Alongside this distension, the Mg^2+ ions induce the release of cholecystokinin ( CCK). Both distension and CCK act as key stimuli to enhance the propulsive contractions (peristalsis) of the colon, increasing the frequency and force of smooth muscle movement.

Dosage and Administration Information

Official Administration Guidelines (Adults and Adolescents)

Magnesia Cinfa (magnesium hydroxide) is an oral suspension. Administration instructions vary depending on whether the medication is used as an antacid or as a laxative. The medication is only indicated for adults and adolescents aged 12 years and older. Children under 12 years of age must not use this medicine.

Procedural Steps:

  1. Preparation: Shake the container (bottle or sachet) well before measuring the dose.
  2. Administration: Take the dose orally, either directly or mixed with water, juices, or herbal infusions.
  3. Timing and Hydration: It is mandatory to take the lowest dose that is effective. Separation of Magnesia Cinfa intake from other medicines by 2 to 3 hours is necessary. It is highly recommended to drink plenty of liquid (e.g., a full glass, 200 mL) with each laxative dose and maintain adequate fluid intake throughout the day.
Indication Recommended Dose (Adults/Adolescents 12 years) Max Daily Dose Timing/Frequency
As Laxative 5-10 mL up to 25 mL (or 1 to 2 sachets) 25 mL or 2 sachets Single or divided doses; Avoid taking before bedtime.
As Antacid 2.5 mL or 5 mL as needed 12.5 mL Take when symptoms are noted, preferably after meals.

If the symptoms do not improve or worsen after 7 days of continuous treatment, a doctor should be consulted.

Recent Clinical Evidence

Research evidence / Overview of studies for Magnesia Cinfa

This overview summarizes the official scientific evidence and clinical study landscape for the active ingredient in Magnesia Cinfa, Magnesium Hydroxide, focusing solely on the research that was studied for its two primary recognized uses. This information reflects what was observed in studies and does not constitute medical advice or treatment instructions.


Evidence for Occasional Constipation (Laxative Action)

Research has primarily examined the compound in conditions characterized by fluctuating or episodic manifestations of constipation. The evidence base includes Randomized Controlled Trials (RCTs) and various Systematic Reviews that often include comparisons to other substances, such as polyethylene glycol (PEG) or lactulose, used in managing constipation.

Studies explored the substance by monitoring outcomes related to systemic or functional imbalance, such as the number of bowel movements per week (frequency) and stool consistency. Findings reported measurements related to these functional outcomes in the observed populations.

Regulatory and scientific reviews often describe the evidence as Moderate, noting that findings were often varied or mixed across the systematic reviews. Furthermore, results apply only to the populations studied, and research highlights that the certainty of direct comparison data against certain alternative laxatives remains limited.


Evidence for Symptoms of Hyperacidity (Antacid Action)

The evidence base for the antacid property primarily focuses on pharmacological and laboratory studies, rather than large-scale clinical trials. These studies examined the compound's chemical properties. This research is referenced in the documentation supporting its regulatory review for OTC use.

These studies monitored how the pH level within the stomach changes. This research provides insight into short-term changes, and the data show patterns related to neutralization kinetics. Findings suggest this symptomatic effect may be temporary. Regulatory and scientific reviews describe the evidence regarding its basic neutralizing capability as High.


Duration of Studies and Follow-up

Research exploring the compound’s effects in constipation typically spans short-term intervals (less than one week) to intermediate-term durations (up to three months). Evidence derived from these settings provides context but not individual predictions about long-term use. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes on the sustained durability of the observed patterns when used for extended periods.


What is Still Uncertain About Magnesia Cinfa

The evidence landscape highlights several areas where scientific understanding is still developing or limited. For instance, comparative evidence is lacking in high-quality trials against all available contemporary laxatives for chronic constipation. Research often separates the two recognized uses, meaning the evidence provides limited insight into research scenarios focused solely on one recognized action.

Key Studies & References Magnesium Hydroxide (Oral Route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Magnesia Cinfa (FAQ)

Q: How does Magnesia Cinfa compare to other types of laxatives in terms of mechanism?

Regulatory information classifies Magnesium Hydroxide, the active ingredient, as a saline laxative. Its primary mechanism involves creating an osmotic gradient, which means it draws water into the colon. This action is described as different from stimulant laxatives (which directly trigger muscle movement) or bulk-forming laxatives (which add fiber to the stool) in facilitating a bowel movement.


Q: Can Magnesia Cinfa interfere with the body’s absorption of vitamins or other supplements?

Regulatory documents describe that Magnesia Cinfa, like similar medications, may interfere with the absorption of other substances. This potential interference may affect certain vitamins, nutritional supplements, and herbal products. Regulatory sources mandate separating the intake of this medication from other supplements or medicines by at least two to three hours to minimize potential interference.


Q: What steps are generally advised if Magnesia Cinfa does not produce an effect within the expected timeframe?

Official documentation states that if a bowel movement does not occur after the dose, the product’s use should be discontinued and professional medical attention sought. A lack of effect may, in rare cases, be a sign of a serious underlying condition that requires evaluation.


Q: Are there specific age restrictions or weight guidelines for using Magnesia Cinfa?

Official guidelines provide specific administration details based on age group, such as adults and adolescents aged 12 years and older. However, the regulatory information does not generally provide instructions based on a patient’s weight.


Q: Does official guidance specify if Magnesia Cinfa should be taken on an empty stomach or with food?

Timing information is defined based on the intended use. When taken as an antacid, official documents state it is often taken as needed. For laxative use, official documents describe the dose as being taken once daily or in divided doses; taking it at bedtime is noted as a common administration time in regulatory texts.


Q: What symptoms, according to the official documentation, might indicate I should stop using Magnesia Cinfa immediately?

Regulatory documents state that product use should be discontinued, and professional medical attention sought, if rectal bleeding occurs or if the product does not result in a bowel movement. These conditions are noted as signs that may suggest a serious underlying health issue.


Q: Is Magnesia Cinfa generally considered the same as taking a regular magnesium supplement?

Official labeling distinguishes the intended use of Magnesia Cinfa from that of a dietary supplement. Magnesia Cinfa is categorized as an over-the-counter Saline Laxative and Antacid drug, indicated for temporary relief of digestive symptoms, not for meeting daily dietary magnesium needs.


Q: Is it normal to experience stomach cramps or bloating after taking Magnesia Cinfa?

Regulatory safety reviews note that mild abdominal cramping and discomfort, along with bloating and gas, are frequently documented as common side effects associated with the use of magnesium hydroxide as a laxative. These effects are often related to its action of increasing fluid in the digestive tract.


Q: Can the long-term or frequent use of Magnesia Cinfa lead to dependency, according to official warnings?

The official product information specifies that this medicine is indicated for occasional use only. Regulatory warnings state that if a patient needs to use a laxative for more than one week, professional consultation is warranted. This suggests that long-term, unsupervised use is not recommended by regulatory bodies.


Q: How quickly should I expect Magnesia Cinfa to start working after the first use?

Official product information describes an expected onset window for its laxative effect. Regulatory documents state that when used for constipation relief, the product usually produces a bowel movement within 30 minutes to 6 hours after it has been administered.


Q: What is the typical duration of effect for Magnesia Cinfa?

The exact total duration of the effect is not precisely specified in regulatory summaries. However, the product is indicated for short-term, temporary relief, with the onset of the desired bowel movement generally occurring within the first six hours.


Q: What are the signs of a possible allergic reaction to Magnesia Cinfa as listed in the warnings?

Official regulatory warnings describe that signs of a possible allergic reaction necessitate seeking immediate medical attention. These signs can include the development of hives or a rash, experiencing difficult breathing, or having swelling of the face, lips, tongue, or throat.


Q: Does Magnesia Cinfa affect blood pressure or heart rate, based on regulatory information?

While Magnesia Cinfa is designed for localized action, the risk section addresses potential systemic issues in susceptible individuals. Overuse or use in patients with impaired kidney function can lead to a serious electrolyte disturbance called hypermagnesemia. Symptoms of hypermagnesemia described in regulatory information may include an irregular heartbeat and muscle weakness.


Q: What differentiates Magnesia Cinfa from other magnesium-containing products that are not laxatives?

The key distinction is the regulatory indication and labeling. Magnesia Cinfa is officially indicated and regulated as a medication with specific laxative and antacid effects. Other products containing magnesium, such as different salt forms, are typically labeled and marketed as nutritional supplements intended to treat dietary deficiencies.


Q: What advice do official sources give if a dose of Magnesia Cinfa is missed?

Magnesia Cinfa is generally taken on an as-needed basis for temporary relief, rather than on a strict daily schedule. Official documents do not typically provide specific instructions for a missed dose, but they caution against taking the medication more often than directed.

How should Magnesia Cinfa be stored and disposed of?

Storage and Disposal of Magnesia Cinfa

Official regulatory guidelines define specific conditions necessary for storing and disposing of Magnesia Cinfa (Magnesium Hydroxide oral suspension) to maintain product stability and ensure safety.

Storage Requirements

The medicine must be stored at a temperature not exceeding 25°C and it is essential that the product must not be frozen. A mandatory safety rule requires that the medicine be kept out of the sight and reach of children.

Stability and Expiry

Do not use the product after the expiration date (CAD) printed on the packaging. For the multi-dose bottle presentation, the contents must be discarded 6 months after the initial opening.

Disposal Instructions

Medicines must not be disposed of in household waste or flushed down the toilet. All unused or expired product must be taken to a designated pharmaceutical waste collection point (such as a pharmacy collection bin) for correct environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Magnesia Cinfa found in:

A-Z Index: